Genetically engineered mouse CCA models have been reported to show a relatively shorter tumor development time and to recapitulate human CCA with alterations to the cellular proliferation signaling pathways, such as PI3K/AKT. This evidence concerns the gene AKT1 and cholangiocarcinoma.